IQVIA Holdings Inc. $IQV Shares Sold by Nomura Holdings Inc.

Nomura Holdings Inc. lessened its stake in IQVIA Holdings Inc. (NYSE:IQV) by 7.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,288 shares of the medical research company’s stock after selling 397 shares during the quarter. Nomura Holdings Inc.’s holdings in IQVIA were worth $932,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Sowell Financial Services LLC acquired a new stake in shares of IQVIA in the first quarter valued at approximately $305,000. Mather Group LLC. grew its position in IQVIA by 83.5% in the first quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock worth $136,000 after acquiring an additional 350 shares during the period. Private Advisor Group LLC grew its position in IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after acquiring an additional 566 shares during the period. Park Avenue Securities LLC grew its position in IQVIA by 40.4% in the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company’s stock worth $956,000 after acquiring an additional 1,562 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its position in IQVIA by 34.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company’s stock worth $2,338,000 after acquiring an additional 3,398 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

IQVIA Trading Up 0.2%

IQV opened at $184.05 on Thursday. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $250.46. The business has a fifty day simple moving average of $178.75 and a 200-day simple moving average of $167.71. The firm has a market cap of $31.29 billion, a P/E ratio of 26.64, a P/E/G ratio of 2.09 and a beta of 1.32. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analysts’ expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the firm earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

IQV has been the subject of several analyst reports. Redburn Partners set a $214.00 price objective on IQVIA in a research report on Wednesday. Citigroup reiterated a “neutral” rating on shares of IQVIA in a research report on Thursday, May 22nd. Evercore ISI increased their price objective on IQVIA from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 9th. Truist Financial increased their price objective on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, July 23rd. Finally, Barclays increased their price objective on IQVIA from $165.00 to $185.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $229.86.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.